The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Table 3 Basic characteristics of patients with NHL from the study sample

Basic demographic & clinical characteristics	3-weekly regimens (n=28)^a	Dose dense regimens (n=11)^b	All regimens (n=39)
Age range (years)	18-64	20-61	18-64
IPI low, n (%)	7 (25)	4 (36)	11 (28)
IPI low/intermediate, n (%)	11 (39)	3 (27)	14 (36)
IPI high/intermediate, n (%)	5 (18)	1 (9)	6 (15)
IPI high, n (%)	5 (18)	3 (27)	8 (21)
Ann Arbor stade III/IV, n (%)	21 (75)	8 (73)	29 (74)
Prior/concomitant radiotherapy, n (%)	2 (7)	0	2 (5)

Basic demographic and clinical characteristics of the patients with NHL are presented for all 3-weekly chemotherapy regimens, for dose-dense regimens (R-ACVBP-14, ACVBP, R-CHOP-14 and R-etoposide, cyclophosphamide), and for all regimens.
^a 3-weekly regimens were R-CHOP-21 (n = 13), CHOP-21 (n = 3), BVAM (n = 2), R-DHAP (n = 2), R-GEMOX (n = 2), R-COPADEM (n = 2) and Hyper CVAD, ESHAP, methotrexate/vincristine/ifosfamide/dexamethasone, R-ICE (1 patient each).
^b Dose-dense regimens were R-ACVBP-14 (n = 6), ACVBP (n = 2), R-CHOP-14 (n = 2) and R-etoposide-cyclophosphamide (n = 1)

ISSN: 1471-2407